Lenvakast 10 mg (Lenvatinib)

Description

Lenvakast 10 mg (Lenvatinib) is a prescription anti-cancer agent specifically indicated against Renal Cell Carcinoma (RCC) and Differentiated Thyroid Cancer (DTC). For kidney cancer (RCC), everolimus is used in combination with Lenvakast 10 mg to attain a sustainable efficacy. Whereas for thyroid cancer, Lenvakast 10 mg is favoured, if cancer cannot be removed by surgical operation.

Lenvakast 10 mg is taken orally with or without food. Preferably, it should be consumed at the same time each day. For kidney cancer (RCC), 18 mg (1 tablet of 10 mg and 2 tablets of 4 mg) is taken along with 5 mg (1 tablet) everolimus. While, for thyroid cancer (DTC), 24 mg (1 tablet of 4 mg and 2 tablets of 10 mg) is an ideal regimen.

In certain cases, due to the advent of severe side-effects or complications in the kidney or liver, the dosage could be reduced for the safety of the patients. The table below shows the recommended dosage reductions for Lenvakast 10 mg (Lenvatinib) in such conditions.